← Back to patent-cliff list
TNG-260
Tier C — Watch / tradeTNG-260
Tango Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：HDAC1, LSD1, RCOR1
Indications (approved)：Non-small cell lung cancer, Lung cancer, Lung adenocarcinoma, Solid tumour
Regional status
US
Phase II
2023-06-12
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of TNG-260?
Approved indications include: Non-small cell lung cancer, Lung cancer, Lung adenocarcinoma, Solid tumour.
When does the TNG-260 patent expire?
No public expiry year is available for TNG-260 yet; this page updates once verified.
How do I get a quote for TNG-260 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03